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ADDING A GENE DELETING A GENE
Modifying the Mammalian Genome
Pronuclear microinjection ES / iPS cells
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The most relevant and distinctive feature 
among all gene modifying methods is 
Random versus Targeted genetic modification
Slides from 1991
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Fixing the DSB: NHEJ vs HDR

CRISPR
Francisco Juan Martínez Mojica
UA
Mojica and Montoliu ( Trends in Microbiology 2016)
Prokaryotes Eukaryotes
The CRISPR-Cas pioneers
Doudna & Charpentier (2014) ScienceJennifer Doudna
Emmanuelle Charpentier
The CRISPR-Cas System: targeting nucleases to specific DNA sequences






Hiroshi Nishimasu and Osamu Nureki (University of Tokyo)
Shibata et al. Nature Comm. 2017

Gene Editing
CRISPR vs ES cells
• Generation of target 
mutations is faster with 
CRISPR (x3)
• Generation of target 





• INDELs: small insertions and deletions
• KOs: disrupting ORF
• Gene editions: point mutations




Disrupting a gene: KO
• The easiest approach
• almost trivial nowadays
• Many similar alleles will be generated
• Efficient protocol
We use the Tyrosinase gene (Tyr) in mice as experimental 
model to study mammalian gene regulation and … 
…as animal models of OCA1 albinism, a human rare disease 
Mouse Human Albinism Mutations (HGMD)
Tyr TYR OCA1 303
Oca2 OCA2 OCA2 154
Tyrp1 TYRP1 OCA3 16
Slc45a2 SLC45A2 OCA4 78
?? 4q24 OCA5 1
slc24A5 SLC24A5 OCA6 2
Lrmda LRMDA OCA7 6
Gpr143 GPR143 OA1 114
Sl38a8 SLC38A8 FHONDA 8
Lyst LYST CHS1 53
Hps1 HPS1 HPS1 31
Ap3b1 AP3B1 HPS2 20
Hps3 HPS3 HPS3 7
Hps4 HPS4 HPS4 13
Hps5 HPS5 HPS5 11
Hps6 HPS6 HPS6 9
Dtnbp1 DTNBP1 HPS7 2
Bloc1s3 BLOC1S3 HPS8 2
Bloc1s6 BLOC1S6 HPS9 2
Ap3d1 AP3D1 HPS10 1
There are at least 20 genes associated with albinism






























• Relatively straight forward, many alleles will be 
generated
• INDELs at both targeting sites will be also generated
• Consider inversions can also be generated
• Efficient protocol
Mutations in regulatory elements could possibly account for OCAI individuals (~30%)
in which no other alterations are found within the tyrosinase locus
Oculocutaneous albinism type I
Relevance of regulatory elements at the endogenous Tyr locus
Montoliu et al. PCMR 2014; Montoliu & Marks PCMR 2016
DNA coding sequences represent 2% genome
DNA non-coding sequences represent 98% genome
DNA non-coding sequences contain mainly:
DNA repetitive elements, mobile elements and 
DNA regulatory elements
The non-coding genome
Alternative: using CRISPR-Cas9 genome editing 




Founder mosaic mice with clear coat colour pigmentation 
phenotype carrying BIALLELIC deletion of Tyr 5’ boundary
Deleting Tyr 5’ boundary with CRISPRs in vivo
Many mutant deletion alleles generated upon targeting
the 5’ Tyr Boundary by CRISPR-Cas9
Seruggia et al. 2015 NAR
Comparing different Tyr
5’ Boundary targeted 
alleles with similar 
phenotypes reveals the 










• Relatively straight forward, but can be challenging, many alleles will 
be generated
• INDELs will mostly be also generated
• Relatively doable protocol (however, if expected mutation not found, 
the number of embryos/animals to be used rapidly increases)



















El Málaga juega en primera división
El Málaga juega en primera división
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INDELs – Gene disruption Gene repair / edit
Current limitations of CRISPR
• On-target uncertainty: many alleles are generated
through NHEJ
• Most/all founder edited-organisms are mosaic
• Error-prone NHEJ is the default repairing pathway
• Donor template-specific HDR is not the preferred
repairing pathway
• Off-targets: similar target sequences can be altered
• Reaching a significant number of target cells (viral & 
non-viral delivery systems)














Off-targets: we can deal with them
• Off-targets depend mainly on the selected guide
RNA and, to a lesser extent, on the Cas 
(different Cas have different properties)
• New algorithms developed for selecting optimal
guide RNAs (Breaking-Cas, CRISPOR, Crispr-
GOLD…)
• Can be reduced to an acceptable minimum by
reducing the amount (Cas protein, not RNA or
DNA) and the time of action of Cas nucleases 
(inhibitors)
Oliveros et al. Nucleic Acids Res. 2016
Improved design of RNA guides for optimized CRISPR experiments
http://bioinfogp.cnb.csic.es/tools/breakingcas/
Google for “Breaking Cas”
We have not found
off-target sites with




Mostly observed in vitro
Seruggia et al. 2015 NAR
• Founder animals are 
nearly always complex
mosaic
• Many different alleles
can be present
• Not all of them might
transmit through
germline
One 8-cell embryo = 16 possible alleles










































Multiple alleles present in CRISPR founder gene-edited mice
Doudna & Charpentier (2014) Science
CRISPR-Cas is the future
CRISPR tools and somatic gene therapy 









with diverse tropism  
to different cellular types
Cargo ~4.7 kb
Increasing number of animal models of rare
monogenic diseases corrected via CRISPR
• Duchenne muscular distrophy (DMD)
• Ornithine transcarbamylase (OTC) deficiency
• Hereditary tyrosinemia I (FAH deficiency)
• Congenital cataract (CRYGC)
• Chronic granulomatous disease (CGD)
• Retinitis pigmentosa (RP)
• Leber congenital amaurosis (LCA)
• Hungtinton Disease (HD)
• …
• Also many iPS cells models correcting gene mutations via
CRISPR strategies
Preclinical animal models
Flyn et al. (2015) Experimental Hematology
CRISPR-mediated 
gene therapy of a 
human rare disease: 
chronic granulomatous 
disease (CGD) in 
human iPS cells
Challenge: 
multiple alleles are 
generated
Challenges for CRISPR-mediated 
gene therapy in patients
• Immune response against Cas9 
• Immune response against AAV 
• Finding the right AAV serotype (preferential)
• Non-viral delivery systems (nanoparticles, liposomes) 
the future
• Reaching a significant number of target cells
• On-target allelic multiplicity (indetermination)
• Off-targets
• HDR (dividing cells) versus NHEJ (quiescent cells/neurons) 
HITI (homology-independent targeted integration)
Niosomes
J.L. Pedraz (UPV/EHU)
Cas9: Bang Wong, Broad Institute of Harvard and MIT, Cambridge, MA
• Cas9 antibodies
found in human 
serum
• Anti-Cas9 T 
lymphocites found in 
human blood
• 79% individuals have
antibodies against
SaCas9
• 65% individuals have
antibodies against
SpCas9







Feng Zhang’s lab (Zetsche et all. Cell, Sep 2015)
Cas12a Francisella tularensis 
Doudna & Charpentier (2014) Science
Targeti
p300
Targeting acetylation of Histone H3 Lysine 27 in the genome
Epigenome editing by a CRISPR-Cas9-based 
acetyltransferase activates genes from 
promoters and enhancers
Hilton et al. 
Nature Biotechnology  33, 510–517 (2015)
Activating gene expression
by CRISPR-dCas9/p300
Liu et al. Cell 2018
CRISPR-Cas rescues Fragile X syndrome
Liao et al. Cell 2017
CRISPR-derived
BASE EDITORS
C U  T
A I  G
David Liu Lab
Kim et al. Nat Biotech. 2017
CRISPR 2.0 (editing RNA)
Feng Zhang’s Lab Nature 2017
CRISPR-Cas
as a diagnostic tool
1
Gootenberg et al. Science 2017
Feng Zhang Lab









Marta Sánchez Pawel Pelczar (Univ. Zürich / Univ. Basel) Transgenic Unit
Belén Pintado (CNB-CSIC, Madrid) Transgenic Unit
Juan Carlos Oliveros (CNB-CSIC, Madrid) Bioinformatics
Former members: Davide Seruggia, Mónica Martínez, Irene Robles, Irene 
Sánchez, Esther Zurita, Magdalena Hryhorowicz, Barbara Franck, Rafael 
Jiménez, Cesar Echeverria, Celia de Lara, Iván Caballero, Yaiza López …
Lluís Montoliu’s Lab at CNB
http://www.cnb.csic.es/~montoliu/
Cryopreservation and Histology teams: Julia Fernández, María Jesús 
del Hierro, Marta Castrillo, Soledad Montalbán, Óscar Sánchez
Fotos: Ana Ytyrralde
www.cnb.csic.es/~montoliu/CRISPR/
Google for CNB + CRISPR
The CRISPR web page at CNB
www.albinismo.es
